What they were paid
HALOZYME THERAPEUTICS Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $140,000 | $250,025 | $150,014 | $0 | $540,039 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HALOZYME THERAPEUTICS, INC. DEF 14A filed March 23, 2026, accession 0001159036-26-000041, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025HALOZYME THERAPEUTICS pays directors a $50,000 cash retainer and $400,000 in RSUs and Options.
Committees
FY2025 · as the proxy prints themAudit
The rest of the HALOZYME THERAPEUTICS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Barbara Duncan | Independent Director | $490,039 |
| Bernadette Connaughton | Independent Director | $470,039 |
| Helen I. Torley | Director | $0 |
| James Lang | Independent Director | $3,668 |
| Mahesh Krishnan | Independent Director | $461,715 |
| Matthew L. Posard | Independent Director | $475,039 |
| Moni Miyashita | Independent Director | $455,039 |
The full HALOZYME THERAPEUTICS compensation record
free company briefThis page is one director within HALOZYME THERAPEUTICS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat